Vinpocetine CAS: 42971-09-5

Synonyms: 3A,16A-APOVINCAMINIC ACID ETHYL ESTER;(3A,16A)-EBURNAMENINE-14-CARBOXYLIC ACID ETHYL ESTER;CAVINTON;ETHYL APOVINCAMIN-22-OATE;EBURNAMENINE;EBURNAMENINE-14-CARBOXYLIC ACID ETHYL ESTER;RGH-4405;VINPOCETIN

MF: C22H26N2O2

MW: 350.45

EINECS: 256-028-0

Chemical Properties White Crystalline Solid

Usage A calcium/calmodulin-dependent phosphodiesterase 1 (PDE1) inhibitor

Usage A derivative of Vincamine with vasodilating activity. Vasodilator (cerebral).

Usage calcium regulator

Usage Gleevec metabolite, tyrosine kinase inhibitor

Biological Activity Phosphodiesterase inhibitor, selective for PDE1 (IC 50 = 21 μ M). Also blocks voltage-gated Na + channels.

Vinpocetine (brand names: Cavinton, Intelectol; chemical name: ethyl apovincaminate) is a synthetic derivative of the vinca alkaloid vincamine (sometimes described as “a synthetic ethyl ester of apovincamine”), an extract from the lesser periwinkle plant. Vinpocetine was first isolated from the plant in 1975 by the Hungarian chemist Csaba Szántay. The mass production of the synthetic compound was started in 1978 by the Hungarian pharmaceutical company Richter Gedeon.

Vinpocetine is not FDA approved in the United States for therapeutic use. The U.S. Food & Drug Administration (FDA) has ruled that vinpocetine, due to its synthetic nature and proposed therapeutic uses, was ineligible to be marketed as dietary supplement under the Federal Food, Drug, and Cosmetic Act